Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...

"Although the α-D-ribofuranoside structure is frequently found in natural products, there have been fewer reports of the synthesis of α-D-ribofuranosides than of the β-anomers. Thus, the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk. New final overall ...

The addition of LuPSMA to enzalutamide reduced the risk of death by 45% vs enzalutamide alone. The median OS was 34 months (95% CI, 30-37) with the combination compared to 26 months (95% CI, 23-31) ...

Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...

Mevrometostat combined with enzalutamide improved median rPFS to 14.3 months versus 6.2 months with enzalutamide alone in mCRPC patients. The combination therapy showed a higher objective response ...